Who May Be a Candidate for Neuromodulation? Conditions, Prior Treatments and Testing

The folder on the kitchen table has grown thick. Physical therapy notes from two different practices. Three sets of injection records. A surgical report from four years ago that promised more than it delivered. Somewhere near the bottom is a new phrase, written in a pain specialist’s handwriting: consider neuromodulation.

For the person reading that note, the question is not really what the device does. It is whether they are the sort of patient it was designed for. Who is a candidate for neuromodulation, and who is politely told to try something else first? That answer turns out to be less about how badly someone hurts and more about the shape of their problem, what has already been tried, and what a series of tests reveals.

This explainer walks through those criteria the way a clinic evaluation actually unfolds: condition first, treatment history second, testing third, and the decision, always, left with the treating team.

Neuromodulation explained: what the word covers, and what it does not

Neuromodulation is a family of treatments that change how nerves send signals, usually with gentle electrical pulses delivered by an implanted device, rather than by cutting, burning, or numbing the nerve. The phrase covers several very different procedures that happen to share an engineering idea.

Spinal cord stimulation places thin wires, called leads, in the space just outside the spinal cord’s protective covering. Sacral neuromodulation places a lead beside a nerve root in the lower back that helps control the bladder and bowel. Peripheral nerve stimulation targets a single nerve in an arm, leg, or the back of the head. Deep brain stimulation places electrodes inside specific brain structures, and vagus nerve stimulation wraps a small coil around a nerve in the neck. Each device connects to a pulse generator, a battery-powered unit roughly the size of a large watch face, which sits under the skin and can be adjusted from outside the body (Cleveland Clinic; Mayo Clinic).

What neuromodulation does not do matters just as much. It does not repair a herniated disc, a narrowed spinal canal, or a torn ligament. It does not replace a missing neurotransmitter. It changes the traffic on the nerve, not the road itself. That single fact explains most of the candidacy rules that follow: if a structural problem can still be fixed, most teams want it fixed first, and if the pain or bladder signal does not travel along a route the device can reach, stimulation has nothing useful to modulate.

So “candidate” is the right word. Nobody is simply prescribed a stimulator. People are screened for one, and a fair share of that screening is designed to find reasons the device may not help, before anything is implanted.

How neuromodulation actually works, in plain language

Picture a busy junction where pain messages from the leg arrive at the spinal cord before heading up to the brain. Spinal cord stimulation delivers a steady, low-intensity electrical signal into that junction. The classic explanation, sometimes called the gate control theory, is that the stimulation competes with the pain traffic so that less of it gets through. Older systems produce a tingling sensation, called paresthesia, that patients feel over the painful area; newer programming patterns, including high-frequency and burst settings, can work without any noticeable tingling (Johns Hopkins Medicine; Cleveland Clinic).

The hardware is simpler than most people expect. One or two leads sit in the epidural space, the narrow gap between the bone of the spine and the membrane around the spinal cord. A wire runs under the skin to the pulse generator, usually tucked into the upper buttock or flank. A handheld controller lets the patient switch programs, adjust intensity within limits set by the clinic, and turn the device off. The clinic reprograms the settings during follow-up visits.

Sacral neuromodulation works on a different principle. The lead rests next to the third sacral nerve root, which carries signals between the spinal cord and the bladder, pelvic floor, and rectum. Mild stimulation there appears to calm the reflex that makes an overactive bladder contract at the wrong moment, and it can also help a bladder that will not empty for non-obstructive reasons (NIH StatPearls; Cleveland Clinic).

Deep brain stimulation reaches further still. Electrodes placed in movement-control circuits deliver pulses that interrupt the abnormal firing patterns behind tremor and stiffness in Parkinson’s disease and related disorders (Mayo Clinic).

Across all three, two features stand out. The effect is adjustable, and the effect is reversible. Turn the device off and the nervous system returns to its previous state. That reversibility is the reason a trial period is possible, and the trial is the heart of candidacy.

What conditions does neuromodulation treat?

The honest answer is: a specific list, not a general one. Neuromodulation is matched to conditions where the problem lives in nerve signaling and where a device can physically reach the relevant pathway.

Spinal cord stimulation is most often considered for:

• Persistent pain after spine surgery, sometimes called failed back surgery syndrome, where the operation healed but leg or back pain continued.
• Complex regional pain syndrome, a condition of severe, out-of-proportion limb pain with swelling, skin color and temperature changes, usually after an injury.
• Painful peripheral neuropathy, including nerve damage from diabetes, where burning or shooting pain in the feet has not eased with other care.
• Arachnoiditis and other chronic nerve-root pain where surgery is not a good option.
• Certain kinds of ischemic pain, such as angina that persists despite full cardiac treatment, in selected programs (Johns Hopkins Medicine; Cleveland Clinic).

Sacral neuromodulation is used for overactive bladder with urgency or urge incontinence, for urinary retention that is not caused by a blockage, and for fecal incontinence. It is not a treatment for stress incontinence, the leakage that happens with coughing or lifting, because that problem is mechanical rather than neurological (NIH StatPearls; NHS).

Deep brain stimulation is established for Parkinson’s disease with motor fluctuations, essential tremor, dystonia, and some forms of drug-resistant epilepsy. Vagus nerve stimulation is approved for drug-resistant epilepsy and, in some settings, for depression that has not responded to standard treatment. Peripheral nerve stimulation is used for pain confined to a single nerve territory, such as certain headaches or post-surgical nerve pain (Mayo Clinic).

Notice what is absent from these lists: acute injury, pain with an untreated structural cause, widespread pain without a clear neurological source, and conditions where the diagnosis itself is still uncertain. Those are not failures of the technology. They are simply outside what it was built to do.

Who is a candidate for neuromodulation? The four questions clinicians ask

Strip away the specialist vocabulary and most candidacy evaluations come down to four questions, asked roughly in this order.

Is the diagnosis clear, and is it one that stimulation can plausibly reach? A person with leg pain traced to a specific nerve root fits the model. A person whose pain has never been clearly explained does not, at least not yet. Teams will often go back to imaging and examination before anything else.

Have reasonable, well-documented treatments been given a fair chance? Neuromodulation sits fairly late in most treatment pathways. Guidelines from health services and specialty bodies generally expect that physical rehabilitation, appropriate medicines, and less invasive procedures have been tried and either did not help enough or caused side effects that outweighed benefit (Johns Hopkins Medicine; NHS).

Is there something that should be fixed first? Progressive weakness, a compressed nerve that surgery can relieve, an active infection, or an untreated medical condition all take priority. Stimulation masks a signal; it does not remove a cause.

Can this person live with, operate, and benefit from a device? This is where psychological screening, expectation-setting, and practical questions enter. Someone who expects zero pain is likely to be disappointed and may be counseled to reconsider. Someone with untreated major depression or an active substance use disorder is usually asked to address that first, because those conditions can blunt the benefit and complicate recovery (Cleveland Clinic).

A useful way to hear these questions is that none of them asks how severe the symptom is. Severity alone has never been the ticket. Fit is. The person with moderate, precisely located nerve pain and a stable life may be a stronger candidate than the person in agony whose problem is still undefined. That can feel unfair, but it reflects who the evidence suggests is most likely to be helped rather than harmed.

Prior treatments: what usually has to come first

The word “failed” appears constantly in this field, and it deserves a gentler reading. A treatment is considered to have failed when it was delivered properly, for long enough, and still did not produce enough benefit, or when its side effects were unacceptable. Trying something once, briefly, rarely counts.

For spinal cord stimulation, the expected history typically includes a structured course of physical therapy, medicines from the classes used for nerve pain (certain anticonvulsants and antidepressants work on nerve signaling rather than on mood alone, and anti-inflammatory drugs address a different mechanism), and one or more targeted injections such as epidural steroid injections or nerve blocks. Many patients have also had spine surgery, though this is not a requirement. What matters is that the team can see a documented sequence and understand why each step fell short (Johns Hopkins Medicine; Cleveland Clinic).

For sacral neuromodulation, national guidance places behavioral measures first: bladder training, pelvic floor muscle therapy, adjusting fluid and caffeine intake, and managing constipation. Medicines from the antimuscarinic or beta-3 agonist classes, which relax the bladder muscle through different receptors, come next. Nerve stimulation is considered when these have not worked or cannot be tolerated (NHS; NIH StatPearls).

For deep brain stimulation, the crucial prior treatment is careful optimization of standard Parkinson’s medicines. Paradoxically, the people most likely to be offered surgery are those whose medicines still work well but wear off unpredictably or cause troublesome involuntary movements. A poor response to medicines is often a sign that stimulation will also disappoint (Mayo Clinic).

Two cautions. First, any change to medicines during this process belongs with the prescribing clinician; stopping something to “qualify” faster is never advised. Second, prior treatment is about sequence and documentation, not about earning the device through suffering.

Who should not get a spinal cord stimulator, and who is usually asked to wait

Some reasons for saying no are absolute for the moment; others are pauses rather than closed doors. Both are worth understanding before the first appointment.

Common reasons a team will decline or defer spinal cord stimulation include:

• Active infection anywhere in the body, because implanted hardware is a place bacteria can settle.
• A bleeding disorder or anticoagulant therapy that cannot be safely managed around the procedure. Whether and how to pause a blood thinner is a decision for the prescribing physician and the implanting team together, never the patient alone.
• Spinal anatomy that blocks safe lead placement, such as severe scarring or narrowing at the intended level, seen on imaging.
• A structural problem that surgery could still correct, particularly when it is causing weakness or progressive nerve damage.
• Untreated major psychiatric illness or an active substance use disorder, both of which are addressed first because they affect outcomes and the ability to manage a device.
• Inability to operate the controller or attend follow-up programming, whether for cognitive, practical, or other reasons.
• Another implanted electrical device, such as a pacemaker or defibrillator, which requires cardiology input to confirm the two systems will not interfere (Cleveland Clinic; Johns Hopkins Medicine).

Pregnancy is a specific caution, especially for sacral neuromodulation, where safety data are limited; teams often defer implantation and discuss turning an existing device off during pregnancy (NIH StatPearls).

“Asked to wait” describes a different group. Someone recovering from recent surgery, someone whose diabetes or blood pressure is poorly controlled, someone still in the middle of a rehabilitation program that has not run its course. None of these is a judgment. Each is a recognition that the trial and implant carry small but real risks, and that stacking risks is unwise when time may improve the odds.

People sometimes hear “not a candidate” as “nothing more can be done.” It rarely means that. It usually means the current problem list has a different first item.

Types of neuromodulation compared: targets, conditions, and screening

Because the same word covers several procedures, it helps to see them side by side. The table below summarizes where each device acts, what it is usually considered for, and what the pre-implant screening typically involves. It is a map, not a menu; the treating team decides which, if any, applies.

Type	Where it acts	Usually considered for	Typical screening and trial
Spinal cord stimulation	Epidural space beside the spinal cord	Persistent pain after spine surgery, complex regional pain syndrome, painful neuropathy	Spine imaging, medical and psychological evaluation, temporary trial of about a week with an external generator (Cleveland Clinic)
Sacral neuromodulation	Third sacral nerve root in the lower back	Overactive bladder, non-obstructive urinary retention, fecal incontinence	Bladder or bowel diary, urodynamic testing where indicated, staged trial of roughly one to two weeks (Cleveland Clinic; NIH StatPearls)
Peripheral nerve stimulation	A single named nerve in a limb or the head	Pain confined to one nerve territory, some headache disorders	Diagnostic nerve block to confirm the target, sometimes a short trial
Deep brain stimulation	Movement or seizure circuits inside the brain	Parkinson’s disease with fluctuations, essential tremor, dystonia, some epilepsy	Neurological and cognitive testing, brain imaging, assessment of response to standard medicines; no external trial (Mayo Clinic)
Vagus nerve stimulation	Vagus nerve in the neck	Drug-resistant epilepsy, treatment-resistant depression in selected programs	Epilepsy or psychiatric specialist evaluation; no external trial

Three patterns emerge. The pain and bladder devices allow a temporary trial, which is why their candidacy rules lean so heavily on the trial result. The brain and vagus devices do not, so their screening leans harder on diagnosis, medicine response, and cognitive assessment. And every row includes the phrase “evaluation,” because in this field the assessment is not paperwork before the treatment. It is the treatment’s first step.

Who is a candidate for neuromodulation after testing? Imaging, psychology, and the trial

The evaluation that turns “possibly suitable” into “a candidate” usually has three layers, and each can end the process.

Imaging and examination. For spinal cord stimulation, an MRI or CT of the spine checks that the epidural space at the intended level is open enough to accept a lead and looks for anything, such as a compressed nerve, that should be treated another way. A careful neurological examination maps the pain, tests strength and reflexes, and documents the baseline against which any trial will be judged (Johns Hopkins Medicine).

Condition-specific testing. Bladder candidates typically keep a diary for several days, recording fluid intake, voiding times, urgency episodes, and leaks. Many also undergo urodynamic testing, a set of measurements of how the bladder fills, holds, and empties, which distinguishes an overactive bladder from a blockage or a weak muscle (NIH StatPearls). Deep brain stimulation candidates undergo formal cognitive testing, because significant memory or thinking problems raise the risk of worsening after surgery, and an assessment of how well symptoms respond to their usual medicines, since that response predicts the response to stimulation (Mayo Clinic).

Psychological evaluation. Widely expected before spinal cord stimulation and often before other implants, this is an interview and questionnaire session with a psychologist. Its purpose is not to decide whether pain is “real.” It screens for untreated depression, anxiety, or trauma that could interfere with recovery, checks that expectations are realistic, and confirms the person understands what living with a device involves. Many people find it clarifying rather than intrusive (Cleveland Clinic).

Only after these layers does the trial begin. Its logic is simple: instead of predicting whether stimulation will help, the team tries it, temporarily, and measures. For the pain and bladder devices, the trial result carries more weight than any single test above it. A person can pass every screen and still be told, after the trial, that a permanent device is not recommended. That outcome is disappointing, but it is the system working as designed.

The trial stimulation: what the days and weeks usually look like

For spinal cord stimulation, the trial is an outpatient procedure. Under local anesthetic and light sedation, the physician threads one or two temporary leads through a needle into the epidural space, guided by X-ray. The leads exit the skin and connect to a small external generator worn on a belt. Most people go home the same day. The trial typically lasts about a week (Cleveland Clinic).

Those days have a rhythm. The clinic usually asks for a simple daily record: pain scores, activity, sleep, and any change in medicine use, all recorded with the prescribing clinician’s knowledge. Patients are asked to move normally within limits, but to avoid bending, twisting, lifting, and getting the dressing wet, because the temporary leads can shift. A representative or nurse may adjust settings by phone or in person.

At the end, the leads are removed in a few minutes in the clinic. The conversation that follows is the real decision point. Many programs use meaningful relief of roughly half or more of the pain, together with improved function, as the threshold for recommending a permanent device (Johns Hopkins Medicine). Below that, most teams advise against proceeding.

If the trial is judged successful and the person chooses to go ahead, the permanent implant is a separate procedure, usually a few weeks later. Recovery involves several weeks of restrictions on bending and lifting, commonly around six, while the leads scar into position, followed by programming visits to fine-tune the settings (Cleveland Clinic). Battery life depends on the model: non-rechargeable generators last on the order of a few years, rechargeable ones roughly a decade, and replacement is a smaller procedure (Cleveland Clinic).

Sacral neuromodulation follows a similar arc, with a staged trial lasting roughly one to two weeks during which the bladder or bowel diary continues (Cleveland Clinic). Deep brain stimulation skips the external trial entirely; its “trial” is the months of careful programming after surgery, when settings and medicines are adjusted together by the neurology team (Mayo Clinic).

Does neuromodulation actually work? What the evidence shows, and the risks and alternatives

The fairest summary is that neuromodulation helps a meaningful proportion of carefully selected people, does not help everyone, and works best when the selection is honest. That is precisely why the trial exists.

For spinal cord stimulation, randomized trials comparing it with continued medical management in persistent post-surgical pain and complex regional pain syndrome have generally favored stimulation, but relief often diminishes over years, and more recent trials with sham comparisons have produced smaller or uncertain effects for some newer programming modes. Major medical centers state plainly that some patients lose benefit over time and that a minority later have the device removed (Cleveland Clinic; Johns Hopkins Medicine). For sacral neuromodulation, evidence in overactive bladder and fecal incontinence is stronger and more durable, though not universal (NIH StatPearls). For deep brain stimulation in Parkinson’s disease, benefit for tremor, stiffness, and medicine-related fluctuations is well established, while gait, balance, and speech may not improve (Mayo Clinic).

Risks are real but mostly manageable. Leads can move and stop covering the right area, requiring revision. Infection around the hardware occurs in a small percentage of cases and may mean removing the device. Bleeding, a puncture of the membrane around the spinal cord causing a positional headache, and pain at the generator site are recognized complications. Nerve injury is rare but serious. Deep brain stimulation adds surgical brain risks and possible effects on mood or cognition (Cleveland Clinic; Mayo Clinic).

Alternatives do not disappear once neuromodulation is on the table. Multidisciplinary pain rehabilitation programs, continued targeted injections, revision surgery where a correctable lesion exists, and, for a small group, an intrathecal pump that delivers medicine directly to the spinal fluid all remain options. For bladder symptoms, stimulation of the tibial nerve at the ankle with a fine needle is a less invasive form of neuromodulation offered in many services (NHS).

Weighing these is the team’s job, in conversation with the patient. Evidence sets the odds; it does not make the choice.

Sacral neuromodulation candidates, deep brain stimulation, and other forms: how the rules differ

Because spinal cord stimulation dominates the conversation, people with bladder, bowel, or movement conditions sometimes assume the same rules apply to them. Several differ.

Sacral neuromodulation candidates are typically people with urgency, frequency, or urge incontinence from an overactive bladder, urinary retention without a blockage, or fecal incontinence, who have not had enough benefit from behavioral measures and medicines or could not tolerate them (NHS; NIH StatPearls). The device is not suited to stress incontinence, to retention caused by an enlarged prostate or other obstruction, or to bladder problems from a complete spinal cord injury where the nerve pathway itself is interrupted. Pregnancy prompts deferral. The trial is central, exactly as with spinal stimulation, and a noticeable improvement in diary-recorded symptoms is the usual bar for proceeding (Cleveland Clinic).

Deep brain stimulation candidacy turns on diagnosis and medicine response more than on treatment failure. The typical candidate has Parkinson’s disease for several years, still responds well to levodopa, the standard medicine, but experiences wearing-off or involuntary movements that medicines alone can no longer smooth out. People with atypical parkinsonian syndromes usually do not respond. Significant dementia, unstable psychiatric illness, and medical conditions that make brain surgery unsafe are common reasons to decline. Essential tremor and dystonia have their own criteria, again anchored in a confident diagnosis (Mayo Clinic).

Vagus nerve stimulation is considered for people with epilepsy whose seizures continue despite trials of appropriate medicines and who are not candidates for seizure-focus surgery. Peripheral nerve stimulation is reserved for pain that a diagnostic nerve block has traced to one nerve.

The common thread across all of them: the more precisely the problem can be located in the nervous system, the stronger the candidacy. Neuromodulation rewards specificity. It is a poor fit for problems that are diffuse, poorly characterized, or still changing.

What people often get wrong about neuromodulation candidacy

Several beliefs circulate widely enough to steer people wrong before they reach a clinic. Correcting them saves time and, often, disappointment.

“It’s the last resort, so I should try everything, including more surgery, first.” Guidelines place neuromodulation after conservative care, not after every possible operation. For persistent pain following spine surgery, a second or third operation without a clear correctable target often has worse odds than stimulation, and many teams consider a stimulator trial before further surgery (Johns Hopkins Medicine).

“If the trial works, I’ll be pain-free.” The realistic goal is a substantial reduction in pain and an improvement in what a person can do. Complete relief is uncommon. People who expect zero pain tend to rate the same objective result as a failure (Cleveland Clinic).

“A stimulator means I can stop all my medicines.” Some people reduce pain medicine after implantation; others do not. Any change is a decision made with the prescribing clinician, gradually, and never as a condition of qualifying.

“Once it’s in, it’s permanent.” Devices can be switched off, reprogrammed, or removed. Reversibility is one of the reasons they are considered at all.

“You can never have an MRI again.” Many current systems are MRI-conditional, meaning scans are possible under specific conditions and settings. Older systems were more restrictive. The exact rules depend on the implanted model and must be confirmed with the care team before any scan (Cleveland Clinic).

“It’s experimental.” Spinal cord stimulation, sacral neuromodulation, and deep brain stimulation have been used clinically for decades and appear in mainstream guidelines. What remains debated is how large and how durable the benefit is for particular groups, which is a different question.

“Being turned down means my pain isn’t believed.” A decline almost always reflects anatomy, timing, or a mismatch between the problem and the tool. It is not a verdict on the reality of the symptom.

Questions to ask your care team before agreeing to a trial

A good candidacy consultation is a two-way examination. These questions tend to surface the information that matters most, and a thoughtful team will welcome them.

• What specific diagnosis are you treating, and how confident are you that the pain or symptom travels along a pathway this device can reach?
• Which of my previous treatments do you consider adequately tried, and are there any you would want repeated or added before a trial?
• Is there anything on my imaging that could be corrected with surgery instead, and why do you favor stimulation over that option, or the reverse?
• What result during the trial would lead you to recommend a permanent implant, and what result would lead you to advise against it?
• How will my current medicines be managed during and after the trial, and who makes those decisions?
• What are the most common complications you see in your practice, and how are they handled?
• Which type of system are you proposing, and what does that mean for MRI access, battery replacement, and airport or workplace security screening?
• How many programming visits should I expect in the first months, and who do I contact between visits if the stimulation changes?
• If the device stops helping in a few years, what happens next?
• What alternatives, including doing nothing further for now, would you consider reasonable for someone in my situation?

Two habits make these conversations more useful. Bring the folder, or at least a one-page timeline of treatments with dates and outcomes, because candidacy depends heavily on documentation. And bring someone who can listen while you talk; the amount of information in a single visit is easy to underestimate.

The purpose of asking is not to test the clinician. It is to make sure that when the decision is made, it is made by a team and a patient who understand the same facts. That shared understanding is, in the end, the strongest predictor that a person will be satisfied with whatever they decide.

When to call your doctor

Most trial and implant recoveries are uneventful, but a small number of problems need prompt attention, and knowing them in advance removes the guesswork.

Contact the implanting team the same day if you notice any of the following after a trial or permanent procedure:

• Fever, chills, or increasing redness, warmth, swelling, or drainage at any incision or where a lead exits the skin. Infection around hardware is the complication teams most want to hear about early (Cleveland Clinic).
• New or worsening weakness, numbness, or heaviness in the legs or arms, or trouble walking that was not present before.
• Any new difficulty controlling the bladder or bowel, or new numbness around the groin or inner thighs.
• A headache that is severe when upright and eases when lying flat, which can indicate a leak of spinal fluid after lead placement.
• Sudden, sharp, or shock-like stimulation, or a device that stops working or feels very different, since this can signal a lead that has moved.
• Increasing pain at the generator site, or a visible bulge or fluid collection over it.

Call emergency services rather than the clinic for chest pain, shortness of breath, calf swelling with pain, a sudden severe headache unlike previous ones, confusion, seizure, or bleeding that does not stop with firm pressure. These are emergencies regardless of any device.

Between those extremes sits a wider category worth a routine call: pain relief that fades over weeks, a noticeable change in the area the stimulation covers, mood changes after deep brain stimulation, or uncertainty about whether an upcoming MRI, surgery, or dental procedure is compatible with the implant. None of these is urgent, but each is easier to address early.

One final principle underlies all of the above. The care team that evaluated candidacy remains the team responsible for the device. Every adjustment to settings, every medicine decision, and every judgment about whether a symptom is expected or concerning belongs with them. When in doubt, the right move is a phone call, not a wait-and-see.

Frequently asked questions

Who should not get a spinal cord stimulator?

People with an active infection, a bleeding disorder or anticoagulation that cannot be safely managed, spinal anatomy that prevents safe lead placement, or a structural problem that surgery could correct are usually not offered a spinal cord stimulator at that time. Teams also defer implantation for untreated major psychiatric illness, active substance use disorder, or an inability to operate and follow up on the device. Another implanted electrical device requires cardiology review first. Each decision rests with the treating team.

What conditions does neuromodulation treat?

Neuromodulation is matched to specific conditions where nerve signaling drives the problem. Spinal cord stimulation is considered for persistent pain after spine surgery, complex regional pain syndrome, and painful peripheral neuropathy. Sacral neuromodulation treats overactive bladder, urinary retention without obstruction, and fecal incontinence. Deep brain stimulation is established for Parkinson’s disease, essential tremor, dystonia, and some epilepsy, while vagus nerve stimulation is used for drug-resistant epilepsy. Widespread or undiagnosed pain is generally not a fit.

Does neuromodulation actually work?

It helps a meaningful proportion of carefully selected people but not everyone, and benefit can lessen over time. Trials comparing spinal cord stimulation with medical management have generally favored stimulation for certain nerve pain conditions, though more recent sham-controlled studies show smaller or uncertain effects for some newer modes. Evidence for sacral neuromodulation in bladder and bowel symptoms and for deep brain stimulation in Parkinson’s tremor and fluctuations is more consistent. The temporary trial exists precisely because individual response cannot be predicted.

How much does neuromodulation cost?

This article does not quote prices, because they vary widely by health system, device type, and insurance arrangement, and any figure would be misleading. What is consistent is that coverage and approval processes almost always require documented evidence of prior conservative treatment, a formal evaluation, and, for spinal cord and sacral devices, a successful trial period. Your care team and insurer or health service can explain the specific requirements and authorization steps that apply to your situation.

How long does a spinal cord stimulator trial last?

A spinal cord stimulator trial typically lasts about a week, according to major medical centers, during which temporary leads connect to an external generator worn on a belt. Patients keep a daily record of pain, activity, and sleep, avoid bending, twisting, and lifting, and keep the dressing dry. The leads are removed in the clinic afterward. Sacral neuromodulation trials run roughly one to two weeks. The permanent implant, if recommended, is a separate procedure scheduled later.

Do I need a psychological evaluation before neuromodulation?

Most programs expect a psychological evaluation before spinal cord stimulation and often before other implants. It is not a test of whether your pain is real. The psychologist screens for untreated depression, anxiety, or trauma that could interfere with recovery, checks that expectations about pain relief are realistic, and confirms you understand what living with and operating a device involves. Many people find the session clarifying, and it sometimes identifies support that improves outcomes regardless of the implant decision.

Am I a spinal cord stimulator candidate if I have never had back surgery?

Possibly. Previous spine surgery is common among candidates but is not a requirement. What matters is a clear diagnosis of nerve-related pain that stimulation can reach, such as complex regional pain syndrome or painful peripheral neuropathy, along with documented, adequate trials of physical therapy, appropriate medicines, and less invasive procedures. If imaging shows a correctable structural problem, the team may recommend addressing that first. Candidacy is decided by the treating team after evaluation and, usually, a trial.

Who are sacral neuromodulation candidates?

Sacral neuromodulation candidates typically have overactive bladder with urgency or urge incontinence, urinary retention not caused by a blockage, or fecal incontinence, and have not had enough benefit from behavioral measures and medicines or could not tolerate them. The device does not treat stress incontinence or obstructive retention. Evaluation usually includes a bladder or bowel diary and, where indicated, urodynamic testing, followed by a staged trial. Pregnancy generally leads teams to defer implantation.

Can I have an MRI with a neuromodulation device?

Often yes, but only under specific conditions. Many current systems are described as MRI-conditional, meaning scans are possible with particular scanner settings, body regions, and device modes. Older systems and some lead configurations are more restrictive. The exact rules depend on the implanted model, so the care team and the imaging department must confirm compatibility before any scan is booked. Carrying the device identification card helps every clinician you meet check quickly.

Can neuromodulation be removed if it does not help?

Yes. Reversibility is one of the defining features of neuromodulation. A device can be switched off, reprogrammed, or surgically removed, and the nervous system returns to its previous state once stimulation stops. Removal is a smaller procedure than the original implant, though it still carries the usual surgical risks. Because benefit can fade over years, teams monitor response at follow-up visits and discuss options, including removal, if relief is no longer meaningful.

References

• Sacral Neuromodulation: StatPearls, NIH National Library of Medicine
• Urinary Incontinence: Treatment: NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.